

Godrej Consumer

BSE SENSEX
60,078

S&P CNX
17,855

CMP: INR1,038

TP: INR1,250 (+20%)

Buy



CONSUMER PRODUCTS

Stock Info

Bloomberg	GCPL IN
Equity Shares (m)	1,022
M.Cap.(INRb)/(USDb)	1061 / 14.4
52-Week Range (INR)	1139 / 644
1, 6, 12 Rel. Per (%)	-9/24/-13
12M Avg Val (INR M)	1423

Financials Snapshot (INR b)


Y/E March	2021	2022E	2023E
Sales	110.3	122.0	136.1
Sales Gr. (%)	11.3	10.6	11.5
EBITDA	23.9	26.8	31.1
EBITDA mrg. (%)	21.7	21.9	22.8
Adj. PAT	17.7	19.3	23.2
Adj. EPS (INR)	17.3	18.9	22.7
EPS Gr. (%)	21.9	9.5	20.2
BV/Sh.(INR)	92.3	96.8	102.7
Ratios			
RoE (%)	20.4	20.0	22.8
RoCE (%)	18.3	20.5	23.0
Payout (%)	57.9	63.5	61.6
Valuations			
P/E (x)	60.1	54.9	45.7
P/BV (x)	11.2	10.7	10.1
EV/EBITDA (x)	44.5	39.5	33.8
Div. Yield (%)	1.0	1.2	1.3

Shareholding pattern (%)

As On	Jun-21	Mar-21	Jun-20
Promoter	63.2	63.2	63.2
DII	1.2	3.1	3.2
FII	27.0	26.6	26.8
Others	8.6	7.1	6.8

FII Includes depository receipts

Stock Performance (1-year)



Building blocks in place to capitalize on recovery

The management of Godrej Consumer Products (GCPL) held an Analyst Meet with Mr Akhil Chandra to discuss the progress in its Indonesia business. Here are the takeaways:

Key highlights from the interaction

- The Indonesia business has been seeing gradual recovery in demand post the second COVID wave despite a tough macroeconomic situation.
- Given the recent bold economic reforms implemented by the Indonesian government, Mr Chandra is confident GCPL has the building blocks in place to capitalize on these reforms and deliver double-digit profitable growth over the medium term.
- The management aims to drive growth in its largest segment, Household Insecticides (HI), through democratization and premiumization. Furthermore, it would do so by gradually occupying whitespaces within the category by migrating consumers to aerosols and electrical products, wherein it has a stronger presence.
- Hygiene now accounts for 10% of GCPL Indonesia's sales – fairly impressive given GCPL Indonesia's recent entry into the segment. The management is now leveraging its Saniter brand and moving into personal care categories, such as soaps and personal wash with powder-to-liquid and liquid formats.
- Project RISE seeks to dramatically increase GCPL's direct reach as well as SKU throughput per outlet. GCPL's direct reach now stands at 160,000 outlets (from 100,000 earlier). It also has a distribution strategy in place using agents/distributors that now cover 40,000–50,000 outlets. The management believes a 200,000 outlet direct reach is ideal.
- While there has been an increase in some input costs, the scope for price increases is limited, and the management has focused on cost savings and a better mix to offset inflation.
- There are no changes to our estimates. As highlighted in our [recent note](#), GCPL has been performing consistently well in various large categories in the past year, even before the new CEO has taken over (likely in Oct'21). Mr. Sitapati's appointment is an important piece of the puzzle, unlocking the path to strong earnings growth for GCPL. This comes along with a) better capital allocation efforts in recent years, b) the appointment of a new head in the – erstwhile, significantly underperforming – GAUM business (largely Africa), with good initial results in the first year of his tenure in FY21, and c) potential tailwinds in domestic soap and personal wash products – led by more frequent usage since COVID-19 – and a sharp increase in domestic penetration levels in the Hand Wash category.
- Maintain **BUY**, with TP of INR1,250/share (45x Dec'23E EPS).

Krishnan Sambamoorthy – Research analyst (Krishnan.Sambamoorthy@MotilalOswal.com)

Research analyst: Dhairya Dhruv (Dhairya.Dhruv@motilalosal.com) / Kaiwan Jal Olia (Kaiwan.O@MotilalOswal.com)

Investors are advised to refer through important disclosures made at the last page of the Research Report.

Motilal Oswal research is available on www.motilalosal.com/Institutional-Equities, Bloomberg, Thomson Reuters, Factset and S&P Capital.

Macro environment and demand

- Indonesia has been seeing gradual recovery in demand post the second COVID wave despite a tough macroeconomic situation.
- The Indonesian government has been implementing bold economic reforms.
- GCPL's management has put in place building blocks to drive profitable double-digit sales growth over the medium term to capitalize on these government reforms.
- FMCG growth in Indonesia was in the low single digits, as per Nielsen data, even before the first COVID wave last year.
- The category penetration of GCPL's core categories is much higher in Indonesia than in India. For example, Air Fresheners has 30% penetration levels in Indonesia v/s the high single digits in India.
- Unemployment, diminished tourism activity, and reduced working hours have led to consumers downtrading to either smaller packs or private label brands.

Segmental strategy highlights

- In Indonesia, GCPL is the leader in the four key categories in which it is present.
- **Household Insecticides (HI)**
 - HI is the largest category for GCPL Indonesia, with contribution of ~35% to sales. The management's focus is on democratization and premiumization.
 - GCPL has a presence in 40% of the HI market, which is estimated to be worth IDR5t (USD350m). It plans to gradually occupy whitespaces within the category – wherein the salience of coils / personal repellents in the industry is still 30%/10% – by migrating consumers to aerosols and electrical products, wherein it has a stronger presence.
 - The management would focus on the non-mosquito space, with focus on innovating in the roach and rodent portfolios to drive growth.
 - GCPL has gained market share of 50–100 bps in recent years, while the second best player, Baygon by S. C. Johnson, has seen decline in market share.
- **Hygiene**
 - Hygiene now accounts for 10% of GCPL Indonesia's sales despite its recent entry in this category.
 - The management is now moving its Saniter brand from the Non-Personal Care to Personal Care category (soaps, powder-to-liquid, and liquids).
 - There are no plans to enter the Floor Cleaning and Dishwashing categories over the near term, wherein competitors such as Lizol (Unilever) have a very strong presence.
 - In the niche space of Outside-the-Bathroom Hygiene, GCPL has seen its market share grow to 60% after the second COVID wave (from 45–50% earlier).
 - The management believes the brand's medicinal image has helped give it an edge over peers.
- **Air Fresheners** – While this is a Discretionary category, it has seen gradual demand recovery in 1HFY22.
- **Wet Wipes (Mitu brand)** – There has been an unabated price war in the Wet Wipes business in Indonesia for the last six months. GCPL previously had market

share of 10–12% three years ago, which has now seen 400 bps dilution. The management is using tactical initiatives in terms of pricing and sizing to mitigate the competitive onslaught and is confident of regaining lost market share.

- **Hair Care** – Robust growth is seen in the segment. The management focus is on gaining market share from ammonia-based local players instead of competing with L’Oreal’s Garnier. New launches in shampoo and hair color are doing well. The Hair Care portfolio has been static in terms of portfolio salience for the past three years.

Go-to-market strategy

- Project RISE seeks to dramatically increase GCPL’s direct reach as well as SKU throughput per outlet.
- GCPL’s direct reach is now 160,000 outlets from 100,000 earlier. It has also put in place a distribution strategy using spreaders (agents/distributors), which now cover 40,000–50,000 outlets.
- The management believes a 200,000 outlet direct reach is ideal. While Nestlé covers 250,000 outlets, its sales are 6x that of GCPL Indonesia. While Unilever reaches 900,000 outlets directly, 50% of its outlets make up only 5% of its sales.
- The management would also like to increase its indirect coverage through the use of active wholesalers and sub-dealers. It is also entering pilots with spreaders, as well as dedicated B2B players such as Bukalapa, to work on efficiencies to enhance distribution without going direct.
- GCPL is also expanding its pharmacy reach using national distributors.
- It is further bolstering its e-commerce prominence and targets 3% of revenues from the channel next year as well as 10% contribution over the next three years.
- Three years ago, modern trade (MT) / general trade (GT) accounted for 70%/28%. Currently, GT contributes 30%, with e-commerce contributing 2%. The management targets a further ~200bps annual increase in GT share in revenues.

Costs and margins

- Prices of tin cans have spiked on the back of higher iron ore prices.
- Other material costs, such as LPG and raw materials for wipes, have also increased.
- Cost savings is a key area of focus for the management. A better product mix is another lever to mitigate input cost increases.
- While opportunities for price increases are fairly limited, the management has taken modest increases in categories where the likelihood of downtrading is limited.
- The management aims to broadly maintain the margin profile over the short term.
- It has been able to significantly reduced media costs over the last two years owing to some favorable agreements with media houses.
- GT and e-commerce have better margins v/s MT. GT is 1,000bps more margin-accretive than MT.

Other points


- The management has been looking for a bolt-on acquisition for the past 2–3 years and would consider an opportunity if one was to present itself.

Valuation and view

- As highlighted in our [recent note](#), GCPL has been performing consistently well in various large categories for the past year, even before the new CEO takes over (likely in Oct'21).
- We believe Mr Sudhir Sitapati's appointment as MD and CEO for a period of five years could have a transformational change on GCPL's fortunes, as highlighted in our [upgrade note](#).
- Mr Sitapati's appointment is an important piece of the puzzle, unlocking the path to strong earnings growth for GCPL. This comes along with a) better capital allocation efforts in recent years, b) the appointment of a new head in the – erstwhile, significantly underperforming – GAUM business (largely Africa), with good initial results in the first year of his tenure in FY21, and c) potential tailwinds in soap and personal wash products – led by more frequent usage since COVID-19 – and a sharp increase in penetration levels in the Hand Wash category.
- The stock has rallied nearly 50% since the announcement of Mr Sitapati's appointment. However, this spurt is just the first step to what could be the potentially massive revitalization of both earnings and RoCE over the next few years, leading to a sustained re-rating as well. We have seen transformative changes on all these fronts in the past with companies such as BRIT, NEST, JUBI, and HUVR.
- We maintain our **BUY** rating on the stock, valuing GCPL at 45x Dec'23E EPS, arriving at TP of INR1,250.


Story in charts

Exhibit 1: Indonesia's contribution to GCPL's consolidated sales to be 15% in FY22/FY23E




Source: Company, MOFSL

Exhibit 2: Expect GCPL to see 9% CAGR in Indonesia business over FY21–23E...




Source: Company, MOFSL

Exhibit 3: ...with 11% EBITDA CAGR over the same period...




Source: Company, MOFSL

Exhibit 4: ...and EBITDA margin expanding 100bps




Source: Company, MOFSL

Exhibit 5: Expect 11% consolidated sales CAGR over FY21–23E...




Source: Company, MOFSL

Exhibit 6: ...with consolidated EBITDA margin expanding 110bps




Source: Company, MOFSL

Exhibit 7: GCPL to see 14% consolidated EBITDA CAGR over FY21–23E...




Source: Company, MOFSL

Exhibit 8: ...with consolidated adjusted PAT CAGR of 14.7% over the same period




Source: Company, MOFSL

Exhibit 9: GCPL's P/E (x)



Source: Company, MOFSL

Exhibit 10: Consumer sector P/E



Source: Company, MOFSL

Financials and valuations

Income Statement							(INR b)
Y/E March	2017	2018	2019	2020	2021	2022E	2023E
Net Sales	92.7	98.5	103.1	99.1	110.3	122.0	136.1
Change (%)	10.0	6.3	4.7	-3.9	11.3	10.6	11.5
Gross Profit	51.4	55.7	58.1	56.5	61.0	66.4	76.8
Margin (%)	55.4	56.6	56.3	57.0	55.3	54.4	56.4
Total Expenditure	73.7	77.8	81.5	77.7	86.4	95.3	105.0
EBITDA	19.0	20.7	21.7	21.4	23.9	26.8	31.1
Change (%)	16.0	8.9	4.9	-1.2	11.4	12.1	16.0
Margin (%)	20.5	21.0	21.0	21.6	21.7	21.9	22.8
Depreciation	1.4	1.6	1.7	2.0	2.0	2.1	2.1
Int. and Fin. Charges	1.5	1.6	2.2	2.2	1.3	0.8	0.6
Interest Income	0.4	0.7	0.9	0.8	0.7	0.6	0.9
Other Income-rec.	0.3	0.4	0.2	0.4	0.0	0.4	0.5
PBT	16.9	18.6	18.8	18.4	21.2	24.8	29.7
Change (%)	12.4	10.2	1.4	-2.3	15.4	16.9	19.7
Margin (%)	18.2	18.9	18.3	18.6	19.3	20.3	21.8
Tax	3.7	4.0	4.2	3.8	4.1	5.3	6.3
Deferred Tax	-0.1	0.0	0.2	-0.1	0.5	-0.2	-0.2
Tax Rate (%)	22.5	21.8	20.9	21.4	16.9	22.2	21.9
PAT	13.1	14.5	14.9	14.5	17.7	19.3	23.2
Change (%)	12.3	11.2	2.5	-2.9	22.0	9.5	20.2
Margin (%)	14.1	14.8	14.4	14.6	16.0	15.8	17.1
Minority interest	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Group Adjusted PAT	12.9	14.4	14.9	14.5	17.7	19.3	23.2
Non-rec. (Exp.)/Income	0.0	1.8	8.5	0.5	-0.4	0.0	0.0
Reported PAT	13.1	16.3	23.4	15.0	17.2	19.3	23.2

Balance Sheet							(INR b)
Y/E March	2017	2018	2019	2020	2021	2022E	2023E
Share Capital	1.0	1.0	1.0	1.0	1.0	1.0	1.0
Reserves	52.0	61.6	71.6	78.0	93.4	98.0	104.0
Minority Int	0.0	0.0	0.0	0.0	0.0	0.0	0.0
Networth	53.0	62.6	72.7	79.0	94.4	99.0	105.0
Loans	40.0	35.1	33.8	35.2	7.6	7.2	6.9
Deferred Liability	1.9	1.9	-4.7	-5.7	-6.4	-6.4	-6.4
Capital Employed	94.9	99.6	101.8	108.5	95.6	99.8	105.5
Gross Block	36.3	39.6	42.1	45.2	42.0	45.3	48.5
Less: Accum. Depn.	2.1	3.6	4.6	6.3	4.3	6.4	8.5
Net Fixed Assets	34.2	36.0	37.5	38.9	37.7	38.9	40.0
Capital WIP	1.0	0.8	0.5	0.6	0.6	0.6	0.6
Goodwill	46.6	47.2	49.2	53.4	51.3	51.3	51.3
Non Curr Investments	2.5	1.4	0.3	0.3	0.2	0.2	0.2
Current Investments	6.8	8.6	4.8	6.4	6.6	7.2	6.5
Currents Assets	38.3	44.7	43.8	43.5	39.6	45.2	54.2
Inventory	14.1	15.8	15.6	17.0	17.2	17.7	19.8
Account Receivables	10.3	12.5	12.9	11.6	10.0	11.0	12.3
Cash and Bank Balance	9.1	9.6	8.9	7.7	6.7	10.7	16.4
Loans and Advances	4.5	6.8	6.3	7.1	5.7	5.7	5.7
Other Current Assets	0.2	0.1	0.1	0.1	0.0	0.0	0.0
Curr. Liab. & Prov.	34.5	39.0	34.4	34.6	40.5	43.5	47.2
Account Payables	17.2	23.5	25.4	24.8	21.6	23.7	26.5
Other Liabilities	17.2	15.3	8.7	9.3	18.3	19.2	20.2
Net Current Assets	3.8	5.6	9.4	8.9	-0.8	1.6	7.0
Net Assets	94.9	99.6	101.8	108.5	95.6	99.8	105.5

E: MOFSL Estimates

Financials and valuations

Ratios

Y/E March	2017	2018	2019	2020	2021	2022E	2023E
Basic (INR)							
EPS	12.6	14.1	14.6	14.2	17.3	18.9	22.7
Cash EPS	14.0	15.6	16.2	16.1	19.3	21.0	24.8
BV/Share	51.9	61.2	71.1	77.3	92.3	96.8	102.7
DPS	4.0	4.7	6.7	8.0	10.0	12.0	14.0
Payout (%)	31.6	33.2	45.7	56.5	57.9	63.5	61.6
Valuation (x)							
P/E	82.1	73.7	71.2	73.2	60.1	54.9	45.7
Cash P/E	74.0	66.5	63.9	64.5	53.9	49.5	41.8
EV/Sales	11.7	11.0	10.5	11.0	9.6	8.7	7.7
EV/EBITDA	57.4	52.5	50.0	50.8	44.5	39.5	33.8
P/BV	20.0	16.9	14.6	13.4	11.2	10.7	10.1
Dividend Yield	0.4	0.4	0.6	0.8	1.0	1.2	1.3
Return Ratios (%)							
RoE	24.6	24.9	22.0	19.1	20.4	20.0	22.8
RoCE (Post-tax)	16.2	16.2	16.6	15.4	18.3	20.5	23.0
RoIC	18.6	19.3	19.0	16.9	20.7	23.6	27.7
Working Capital Ratios							
Debtor (Days)	41	46	46	43	33	33	33
Asset Turnover (x)	2.6	2.7	2.7	2.5	2.9	3.1	3.4
Leverage Ratio							
Debt/Equity (x)	0.8	0.6	0.5	0.4	0.1	0.1	0.1

Cash Flow Statement

Y/E March	2017	2018	2019	2020	2021	2022E	2023E
(INR b)							
OP/(Loss) before Tax	18.4	20.5	20.4	20.6	23.8	26.5	31.4
Net interest	1.0	0.9	1.4	1.4	0.9	0.1	-0.3
Direct Taxes Paid	-4.3	-4.1	-4.5	-3.6	-4.0	-5.3	-6.3
(Inc)/Dec in WC	3.4	-0.2	0.0	-2.6	-0.5	1.5	0.4
CF from Operations	18.6	17.2	17.3	15.9	20.3	22.8	25.1
Inc in FA	-1.8	-3.1	-2.1	-1.5	-1.6	-3.3	-3.3
Free Cash Flow	16.8	14.1	15.2	14.4	18.7	19.6	21.9
Pur of Investments	-5.7	0.4	2.9	-2.6	-0.1	-0.6	0.7
Others	-16.0	-0.2	1.6	0.0	-1.3	0.5	0.7
CF from Investments	-23.6	-2.9	2.4	-4.2	-3.1	-3.4	-1.8
Inc in Debt	0.0	0.0	0.0	-1.3	-16.2	-0.4	-0.4
Dividend Paid	-2.0	-6.1	-12.3	-8.2	0.0	-14.7	-17.2
Interest Paid	-1.2	-1.6	-2.1	-1.5	-1.6	-0.8	-0.6
Other Item	9.8	-6.1	-6.0	-2.0	-0.4	0.4	0.5
CF from Fin. Activity	6.6	-13.8	-20.4	-13.0	-18.2	-15.4	-17.6
Inc/Dec of Cash	1.7	0.5	-0.7	-1.2	-1.0	4.0	5.7
Add: Beginning Balance	7.5	9.1	9.6	8.9	7.7	6.7	10.7
Closing Balance	9.1	9.6	8.9	7.7	6.7	10.7	16.4

E: MOFSL Estimates

Explanation of Investment Rating	
Investment Rating	Expected return (over 12-month)
BUY	>=15%
SELL	< - 10%
NEUTRAL	< - 10 % to 15%
UNDER REVIEW	Rating may undergo a change
NOT RATED	We have forward looking estimates for the stock but we refrain from assigning recommendation

*In case the recommendation given by the Research Analyst is inconsistent with the investment rating legend for a continuous period of 30 days, the Research Analyst shall within following 30 days take appropriate measures to make the recommendation consistent with the investment rating legend.

Disclosures

The following Disclosures are being made in compliance with the SEBI Research Analyst Regulations 2014 (herein after referred to as the Regulations).

Motilal Oswal Financial Services Ltd. (MOFSL) is a SEBI Registered Research Analyst having registration no. INH000000412. MOFSL, the Research Entity (RE) as defined in the Regulations, is engaged in the business of providing Stock broking services, Investment Advisory Services, Depository participant services & distribution of various financial products. MOFSL is a subsidiary company of Passionate Investment Management Pvt. Ltd.. (PIMPL). MOFSL is a listed public company, the details in respect of which are available on www.motilaloswal.com. MOFSL (erstwhile Motilal Oswal Securities Limited - MOSL) is registered with the Securities & Exchange Board of India (SEBI) and is a registered Trading Member with National Stock Exchange of India Ltd. (NSE) and Bombay Stock Exchange Limited (BSE), Multi Commodity Exchange of India Limited (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) for its stock broking activities & is Depository participant with Central Depository Services Limited (CDSL) National Securities Depository Limited (NSDL), NERL, COMRIS and CCRL and is member of Association of Mutual Funds of India (AMFI) for distribution of financial products and Insurance Regulatory & Development Authority of India (IRDA) as Corporate Agent for insurance products. Details of associate entities of Motilal Oswal Financial Services Limited are available on the website at <http://onlinereports.motilaloswal.com/Dormant/documents/List%20of%20Associate%20companies.pdf>

MOFSL and its associate company(ies), their directors and Research Analyst and their relatives may; (a) from time to time, have a long or short position in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein. (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies) or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report

MOFSL and / or its affiliates do and seek to do business including investment banking with companies covered in its research reports. As a result, the recipients of this report should be aware that MOFSL may have a potential conflict of interest that may affect the objectivity of this report. Compensation of Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions. Details of pending Enquiry Proceedings of Motilal Oswal Financial Services Limited are available on the website at <https://galaxy.motilaloswal.com/ResearchAnalyst/PublishViewLitigation.aspx>

A graph of daily closing prices of securities is available at www.nseindia.com, www.bseindia.com. Research Analyst views on Subject Company may vary based on Fundamental research and Technical Research. Proprietary trading desk of MOFSL or its associates maintains arm's length distance with Research Team as all the activities are segregated from MOFSL research activity and therefore it can have an independent view with regards to Subject Company for which Research Team have expressed their views.

Regional Disclosures (outside India)

This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL & its group companies to registration or licensing requirements within such jurisdictions.

For Hong Kong:

This report is distributed in Hong Kong by Motilal Oswal capital Markets (Hong Kong) Private Limited, a licensed corporation (CE AYY-301) licensed and regulated by the Hong Kong Securities and Futures Commission (SFC) pursuant to the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong) "SFO". As per SEBI (Research Analyst Regulations) 2014 Motilal Oswal Securities (SEBI Reg No. INH000000412) has an agreement with Motilal Oswal capital Markets (Hong Kong) Private Limited for distribution of research report in Hong Kong. This report is intended for distribution only to "Professional Investors" as defined in Part I of Schedule 1 to SFO. Any investment or investment activity to which this document relates is only available to professional investor and will be engaged only with professional investors." Nothing here is an offer or solicitation of these securities, products and services in any jurisdiction where their offer or sale is not qualified or exempt from registration. The Indian Analyst(s) who compile this report is/are not located in Hong Kong & are not conducting Research Analysis in Hong Kong.

For U.S.

Motilal Oswal Financial Services Limited (MOFSL) is not a registered broker - dealer under the U.S. Securities Exchange Act of 1934, as amended (the "1934 act") and under applicable state laws in the United States. In addition MOFSL is not a registered investment adviser under the U.S. Investment Advisers Act of 1940, as amended (the "Advisers Act" and together with the 1934 Act, the "Acts"), and under applicable state laws in the United States. Accordingly, in the absence of specific exemption under the Acts, any brokerage and investment services provided by MOFSL, including the products and services described herein are not available to or intended for U.S. persons. This report is intended for distribution only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the Exchange Act and interpretations thereof by SEC (henceforth referred to as "major institutional investors"). This document must not be acted on or relied on by persons who are not major institutional investors. Any investment or investment activity to which this document relates is only available to major institutional investors and will be engaged in only with major institutional investors. In reliance on the exemption from registration provided by Rule 15a-6 of the U.S. Securities Exchange Act of 1934, as amended (the "Exchange Act") and interpretations thereof by the U.S. Securities and Exchange Commission ("SEC") in order to conduct business with Institutional Investors based in the U.S., MOFSL has entered into a chaperoning agreement with a U.S. registered broker-dealer, Motilal Oswal Securities International Private Limited. ("MOSIPL"). Any business interaction pursuant to this report will have to be executed within the provisions of this chaperoning agreement.

The Research Analysts contributing to the report may not be registered /qualified as research analyst with FINRA. Such research analyst may not be associated persons of the U.S. registered broker-dealer, MOSIPL, and therefore, may not be subject to NASD rule 2711 and NYSE Rule 472 restrictions on communication with a subject company, public appearances and trading securities held by a research analyst account.

For Singapore

In Singapore, this report is being distributed by Motilal Oswal Capital Markets Singapore Pte Ltd ("MOCMSPL") (Co.Reg. NO. 201129401Z) which is a holder of a capital markets services license and an exempt financial adviser in Singapore. As per the approved agreement under Paragraph 9 of Third Schedule of Securities and Futures Act (CAP 289) and Paragraph 11 of First Schedule of Financial Advisors Act (CAP 110) provided to MOCMSPL by Monetary Authority of Singapore. Persons in Singapore should contact MOCMSPL in respect of any matter arising from, or in connection with this report/publication/communication. This report is distributed solely to persons who qualify as "Institutional Investors", of which some of whom may consist of "accredited" institutional investors as defined in section 4A(1) of the Securities and Futures Act, Chapter 289 of Singapore ("the SFA"). Accordingly, if a Singapore person is not or ceases to be such an institutional investor, such Singapore Person must immediately discontinue any use of this Report and inform MOCMSPL.

Specific Disclosures

- 1 MOFSL, Research Analyst and/or his relatives does not have financial interest in the subject company, as they do not have equity holdings in the subject company.
- 2 MOFSL, Research Analyst and/or his relatives do not have actual/beneficial ownership of 1% or more securities in the subject company
- 3 MOFSL, Research Analyst and/or his relatives have not received compensation/other benefits from the subject company in the past 12 months
- 4 MOFSL, Research Analyst and/or his relatives do not have material conflict of interest in the subject company at the time of publication of research report
- 5 Research Analyst has not served as director/officer/employee in the subject company
- 6 MOFSL has not acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- 7 MOFSL has not received compensation for investment banking/ merchant banking/brokerage services from the subject company in the past 12 months

- 8 MOFSL has not received compensation for other than investment banking/merchant banking/brokerage services from the subject company in the past 12 months
 9 MOFSL has not received any compensation or other benefits from third party in connection with the research report
 10 MOFSL has not engaged in market making activity for the subject company

The associates of MOFSL may have:

- financial interest in the subject company
- actual/beneficial ownership of 1% or more securities in the subject company
- received compensation/other benefits from the subject company in the past 12 months
- other potential conflict of interests with respect to any recommendation and other related information and opinions.; however the same shall have no bearing whatsoever on the specific recommendations made by the analyst(s), as the recommendations made by the analyst(s) are completely independent of the views of the associates of MOFSL even though there might exist an inherent conflict of interest in some of the stocks mentioned in the research report.
- acted as a manager or co-manager of public offering of securities of the subject company in past 12 months
- be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the company(ies) discussed herein or act as an advisor or lender/borrower to such company(ies)
- received compensation from the subject company in the past 12 months for investment banking / merchant banking / brokerage services or from other than said services.

The associates of MOFSL has not received any compensation or other benefits from third party in connection with the research report

Above disclosures include beneficial holdings lying in demat account of MOFSL which are opened for proprietary investments only. While calculating beneficial holdings, It does not consider demat accounts which are opened in name of MOFSL for other purposes (i.e holding client securities, collaterals, error trades etc.). MOFSL also earns DP income from clients which are not considered in above disclosures.

Analyst Certification

The views expressed in this research report accurately reflect the personal views of the analyst(s) about the subject securities or issues, and no part of the compensation of the research analyst(s) was, is, or will be directly or indirectly related to the specific recommendations and views expressed by research analyst(s) in this report.

Terms & Conditions:

This report has been prepared by MOFSL and is meant for sole use by the recipient and not for circulation. The report and information contained herein is strictly confidential and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of MOFSL. The report is based on the facts, figures and information that are considered true, correct, reliable and accurate. The intent of this report is not recommendatory in nature. The information is obtained from publicly available media or other sources believed to be reliable. Such information has not been independently verified and no guaranty, representation of warranty, express or implied, is made as to its accuracy, completeness or correctness. All such information and opinions are subject to change without notice. The report is prepared solely for informational purpose and does not constitute an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments for the clients. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. MOFSL will not treat recipients as customers by virtue of their receiving this report.

Disclaimer:

The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent. This report and information herein is solely for informational purpose and may not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. Each recipient of this document should make such investigations as it deems necessary to arrive at an independent evaluation of an investment in the securities of companies referred to in this document (including the merits and risks involved), and should consult its own advisors to determine the merits and risks of such an investment. The investment discussed or views expressed may not be suitable for all investors. Certain transactions -including those involving futures, options, another derivative products as well as non-investment grade securities - involve substantial risk and are not suitable for all investors. No representation or warranty, express or implied, is made as to the accuracy, completeness or fairness of the information and opinions contained in this document. The Disclosures of Interest Statement incorporated in this document is provided solely to enhance the transparency and should not be treated as endorsement of the views expressed in the report. This information is subject to change without any prior notice. The Company reserves the right to make modifications and alternations to this statement as may be required from time to time without any prior approval. MOFSL, its associates, their directors and the employees may from time to time, effect or have effected an own account transaction in, or deal as principal or agent in or for the securities mentioned in this document. They may perform or seek to perform investment banking or other services for, or solicit investment banking or other business from, any company referred to in this report. Each of these entities functions as a separate, distinct and independent of each other. The recipient should take this into account before interpreting the document. This report has been prepared on the basis of information that is already available in publicly accessible media or developed through analysis of MOFSL. The views expressed are those of the analyst, and the Company may or may not subscribe to all the views expressed therein. This document is being supplied to you solely for your information and may not be reproduced, redistributed or passed on, directly or indirectly, to any other person or published, copied, in whole or in part, for any purpose. This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject MOFSL to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction. Neither the Firm, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profits that may arise from or in connection with the use of the information. The person accessing this information specifically agrees to exempt MOFSL or any of its affiliates or employees from, any and all responsibility/liability arising from such misuse and agrees not to hold MOFSL or any of its affiliates or employees responsible for any such misuse and further agrees to hold MOFSL or any of its affiliates or employees free and harmless from all losses, costs, damages, expenses that may be suffered by the person accessing this information due to any errors and delays.

Registered Office Address: Motilal Oswal Tower, Rahimtullah Sayani Road, Opposite Parel ST Depot, Prabhadevi, Mumbai-400025; Tel No.: 022 71934200/ 022-71934263; Website www.motilaloswal.com. CIN no.: L67190MH2005PLC153397. Correspondence Office Address: Palm Spring Centre, 2nd Floor, Palm Court Complex, New Link Road, Malad(West), Mumbai- 400 064. Tel No: 022 7188 1000.

Registration Nos.: Motilal Oswal Financial Services Limited (MOFSL)*: INZ000158836(BSE/NSE/MCX/NCDEX); CDSL and NSDL: IN-DP-16-2015; Research Analyst: INH000000412. AMFI: ARN - 146822; Investment Adviser: INA000007100; Insurance Corporate Agent: CA0579;PMS:INP000006712. Motilal Oswal Asset Management Company Ltd. (MOAMC): PMS (Registration No.: INP00000670); PMS and Mutual Funds are offered through MOAMC which is group company of MOFSL. Motilal Oswal Wealth Management Ltd. (MOWML): PMS (Registration No.: INP000004409) is offered through MOWML, which is a group company of MOFSL. Motilal Oswal Financial Services Limited is a distributor of Mutual Funds, PMS, Fixed Deposit, Bond, NCDs, Insurance Products and IPOs. Real Estate is offered through Motilal Oswal Real Estate Investment Advisors II Pvt. Ltd. which is a group company of MOFSL. Private Equity is offered through Motilal Oswal Private Equity Investment Advisors Pvt. Ltd which is a group company of MOFSL. Research & Advisory services is backed by proper research. Please read the Risk Disclosure Document prescribed by the Stock Exchanges carefully before investing. There is no assurance or guarantee of the returns. Investment in securities market is subject to market risk, read all the related documents carefully before investing. Details of Compliance Officer: Name: Neeraj Agarwal, Email ID: na@motilaloswal.com, Contact No.:022-71881085.

* MOSL has been amalgamated with Motilal Oswal Financial Services Limited (MOFSL) w.e.f August 21, 2018 pursuant to order dated July 30, 2018 issued by Hon'ble National Company Law Tribunal, Mumbai Bench.